Donor age as an independent predictor of inferior outcomes after haploidentical hematopoietic cell transplantation in acute myeloid leukemia. Study conducted on behalf of GETH-TC

This study evaluated the impact of donor age on clinical outcomes in 274 patients with acute myeloid leukemia (AML) haplo-HCT using PTCY-based prophylaxis. Median patient age was 53 years, with 42.6% classified as high-risk AML. The median donor age of 38 years; 31% were under 30. An optimal donor a...

Descripción completa

Detalles Bibliográficos
Autores: Munárriz, Daniel, Pérez-López, Estefanía, Martín Rodríguez, Carlos, Luque, Marta, Esquirol, Albert, Marín Calvo, Carmen, Aparicio, Clara, Peña-Muñóz, Felipe, Heras FErnando, Inmaculada, Oiartzabal Ormtegui, Itziar, Sáez Marín, Adolfo, Fernández Luis, Sara, Domínguez García, Juan José, Villar Fernández, Sara, López-Lorenzo, José Luis, Acosta Fleitas, Cynthia, González-Rodríguez, Ana Pilar, García, Lucía, Torrado, Tamara, Filaferro, Silvia
Tipo de recurso: artículo
Fecha de publicación:2025
País:España
Institución:Universidad de Cantabria (UC)
Repositorio:UCrea Repositorio Abierto de la Universidad de Cantabria
Idioma:inglés
OAI Identifier:oai:dnet:ucreareposit::7629752fe52b8fcc686e4215e278f23c
Acceso en línea:https://hdl.handle.net/10902/39810
Access Level:acceso abierto
Palabra clave:Donor age
Allo-HCT
Haplo-HCT
PTCY
AML
Descripción
Sumario:This study evaluated the impact of donor age on clinical outcomes in 274 patients with acute myeloid leukemia (AML) haplo-HCT using PTCY-based prophylaxis. Median patient age was 53 years, with 42.6% classified as high-risk AML. The median donor age of 38 years; 31% were under 30. An optimal donor age cut-off of 30 years was identified through ROC analysis. Patients receiving grafts from younger donors (<30 years) showed lower rates of aGVHD grade II-IV (3.0% vs. 19.9%, p < 0.001) and grade III-IV (1.5% vs. 10.2%, p = 0.034), with no differences in cGVHD or relapse rates. Overall survival (OS) was higher in the younger donor group (2-year: 80.6% vs. 64.3%, p = 0.011), along by lower non-relapse mortality (NRM) (2-year: 11.1% vs. 23.2%, p = 0.031). Multivariate analysis confirmed donor age 30 years as an independent adverse factor for OS (HR: 1.88, p = 0.019) and NRM (HR: 2.06, p = 0.049), along with older recipient age, higher HCT-CI score, and high-risk AML. These findings suggest that younger donor age contributes to improved survival, primarily through reduced NRM and aGVHD, supporting prioritization of younger donors when multiple haploidentical options are available to optimize transplant outcomes.

Similares en LA Referencia